文献速递临床试验与 GCP基础与转化研究

阿巴西普预防临床前期类风湿关节炎的多中心随机双盲安慰剂对照试验方案(APIPPRA研究)

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.
PubMed 文献 · Trials · 2019-07-15

APIPPRA试验旨在评估阿巴西普在类风湿关节炎临床前期预防或延缓炎症性关节炎发生的可行性、可接受性和有效性。研究计划招募206例至少18岁、有炎症性关节痛且类风湿关节炎相关血清自身抗体阳性的受试者,随机接受52周阿巴西普或安慰剂治疗并随访52周。主要终点为首次出现至少3个肿胀关节或满足2010年ACR/EULAR类风湿关节炎分类标准(基于肿胀而非压痛关节)的时间。

要点

  • 阿巴西普用于类风湿关节炎临床前期预防的可行性、可接受性和有效性尚待验证。
  • 主要终点为首次出现至少3个肿胀关节或满足2010年ACR/EULAR分类标准的时间。
  • 研究采用多中心、随机、双盲、平行组、安慰剂对照设计,治疗52周并随访52周。

核心结论

  • 评估52周阿巴西普治疗在类风湿关节炎临床前期预防或延缓炎症性关节炎发生的可行性、可接受性和有效性。

研究设计与样本

  • 多中心、随机、双盲、平行组、安慰剂对照试验方案。
  • 计划从英国和荷兰的二级保健医院招募206例至少18岁的男性和女性受试者。
  • 受试者需有炎症性关节痛(临床可疑关节痛)且类风湿关节炎相关血清自身抗体阳性。
  • 受试者随机接受每周注射阿巴西普或安慰剂,治疗52周,随后再随访52周。

关键数值与推荐

  • 主要终点定义为首次出现至少3个肿胀关节或满足2010年ACR/EULAR类风湿关节炎分类标准(基于肿胀而非压痛关节)的时间,以先发生者为准。
  • 肿胀关节均需经超声确认。
  • 受试者、护理人员和结果评估者均对分组设盲,临床评估者和超声检查者在研究期间对彼此的评估设盲。
  • 试验注册号:ISRCTN46017566,注册日期2014年7月4日。

局限性

  • 针对炎症性关节疾病预防的试验设计和实施经验有限。
  • 定义「高风险」状态存在挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TRIAL DESIGN: We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for preventing or delaying the onset of inflammatory arthritis. METHODS: The study aimed to recruit 206 male or female subjects from the secondary care hospital setting across the UK and the Netherlands. Participants who were at least 18 years old, who reported inflammatory sounding joint pain (clinically suspicious arthralgia) and who were found to be positive for serum autoantibodies associated with rheumatoid arthritis (RA) were eligible for enrolment. All study subjects were randomly assigned to receive weekly injections of investigational medicinal product, either abatacept or placebo treatment over the course of a 52-week period. Participants were followed up for a further 52 weeks. The primary endpoint was defined as the time to development of at least three swollen joints or to the fulfilment of the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA using swollen but not tender joints, whichever endpoint was met first. In either case, swollen joints were confirmed by ultrasonography. Participants, care givers, and those assessing the outcomes were all blinded to group assignment. Clinical assessors and ultrasonographers were also blinded to each other's assessments for the duration of the study. CONCLUSIONS: There is limited experience of the design and implementation of trials for the prevention of inflammatory joint diseases. We discuss the rationale behind choice and duration of treatment and the challenges associated with defining the "at risk" state and offer pragmatic solutions in the protocol to enrolling subjects at risk of RA. TRIAL REGISTRATION: Current Controlled Trials, ID: ISRCTN46017566 . Registered on 4 July 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Al-Laith M, Jasenecova M, Abraham S, et al. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019. PMID: 31307535. doi:10.1186/s13063-019-3403-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。